新型冠状病毒肺炎与心血管系统。
COVID-19 and the cardiovascular system.
机构信息
Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou, China.
出版信息
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）通过 ACE2 受体感染宿主细胞，导致与冠状病毒病（COVID-19）相关的肺炎，同时也导致急性心肌损伤和心血管系统的慢性损伤。因此，在治疗 COVID-19 期间应特别注意心血管保护。
相似文献
1
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
2
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
3
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
4
Cardiovascular molecular mechanisms of disease with COVID-19.新型冠状病毒肺炎相关疾病的心血管分子机制
J Mol Cell Cardiol. 2020 Apr;141:107. doi: 10.1016/j.yjmcc.2020.04.010. Epub 2020 Apr 11.
5
Coronavirus disease 2019 and the cardiovascular system: Impacts and implications.2019冠状病毒病与心血管系统：影响与启示。
Indian Heart J. 2020 Jan-Feb;72(1):1-6. doi: 10.1016/j.ihj.2020.03.006. Epub 2020 Apr 9.
6
COVID-19 and Cardiovascular Disease.新型冠状病毒肺炎与心血管疾病。
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
7
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
8
Cardiovascular disease and the impact of COVID-19.心血管疾病与2019冠状病毒病的影响
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
9
[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].[2019新型冠状病毒、血管紧张素转换酶2与心血管药物]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):532-538. doi: 10.3760/cma.j.cn112148-20200308-00171.
引用本文的文献
1
History of COVID-19 as a Risk Factor for Cardiac Arrhythmias: A Case-Control Study.新冠病毒病病史作为心律失常的一个风险因素：一项病例对照研究。
Cardiol Res. 2025 Jun 9;16(4):331-337. doi: 10.14740/cr2042. eCollection 2025 Aug.
2
The main protease (M) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII.新型冠状病毒（SARS-CoV-2）的主要蛋白酶（M）通过激活凝血因子VII和FXII在体外引发血浆凝固。
Commun Biol. 2025 Aug 1;8(1):1145. doi: 10.1038/s42003-025-08570-2.
3
The C2HEST score on admission to hospital may successfully predict clinical outcomes of COVID-19 in the all-comers population.入院时的C2HEST评分可能成功预测所有患者人群中COVID-19的临床结局。
Arch Med Sci. 2024 Jul 28;21(3):817-827. doi: 10.5114/aoms/190744. eCollection 2025.
4
Plasma Soluble ST2 as a Prognostic Biomarker for Cardiovascular Events and Mortality in COVID-19 Patients.血浆可溶性ST2作为COVID-19患者心血管事件和死亡率的预后生物标志物。
J Cardiovasc Dev Dis. 2025 Jul 17;12(7):273. doi: 10.3390/jcdd12070273.
5
Association of DHEAS levels with COVID19 severity, gender, age, comorbidities, and management strategies.硫酸脱氢表雄酮（DHEAS）水平与新型冠状病毒肺炎（COVID-19）严重程度、性别、年龄、合并症及治疗策略的关联
Sci Rep. 2025 Jul 1;15(1):21348. doi: 10.1038/s41598-025-05919-9.
6
SARS-CoV-2 Coronavirus Disease in Patients with Underlying Congenital Inferior Vena Cava Anomalies.患有先天性下腔静脉异常的患者中的新型冠状病毒肺炎
Biomedicines. 2025 May 29;13(6):1336. doi: 10.3390/biomedicines13061336.
7
The Impact of COVID-19 on Graft Vasculopathy and Postoperative Thromboembolism in CABG Patients: A Prospective Controlled Study.新冠病毒病对冠状动脉旁路移植术患者移植血管病变及术后血栓栓塞的影响：一项前瞻性对照研究
Cardiovasc Toxicol. 2025 Jun 10. doi: 10.1007/s12012-025-10017-3.
8
Discussion: COVID-19's impact on sports and athletes.讨论：2019冠状病毒病对体育和运动员的影响。
Ger J Exerc Sport Res. 2021;51(3):390-393. doi: 10.1007/s12662-021-00726-6. Epub 2021 Jun 28.
9
Understanding the interplay between COVID-19 and diabetes: insights for the post-pandemic era.了解2019冠状病毒病与糖尿病之间的相互作用：大流行后时代的见解。
Front Endocrinol (Lausanne). 2025 May 21;16:1599969. doi: 10.3389/fendo.2025.1599969. eCollection 2025.
10
Evaluating the impact of COVID-19 on cancer care: a comprehensive analysis of treatment modifications, risk factors, and patient outcomes.评估2019冠状病毒病对癌症护理的影响：对治疗调整、风险因素和患者结局的综合分析。
BMC Infect Dis. 2025 Jun 2;25(1):779. doi: 10.1186/s12879-025-11172-2.
本文引用的文献
1
Notice of Retraction and Replacement. Gander et al. Association Between Dialysis Facility Ownership and Access to Kidney Transplantation. JAMA. 2019;322(10):957-973.撤稿及替换通知。甘德等人。透析设施所有权与肾移植可及性之间的关联。《美国医学会杂志》。2019年；322(10):957 - 973。
JAMA. 2020 Apr 21;323(15):1509-1510. doi: 10.1001/jama.2020.2328.
2
The embryonic origin of endocrine cells of the gastrointestinal tract.胃肠道内分泌细胞的胚胎起源。
Gen Comp Endocrinol. 1982 Jun;47(2):249-65. doi: 10.1016/0016-6480(82)90228-3.
Zotero 插件